Alain Moga
Research Subjects
Alain Moga has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ambre De Pooter1 shared publication
- Andrew Brown
Quintis Pty Ltd. Level 1, 87 Colin Street, West Perth 6005, Australia
1 shared publication - Arnaud Fontbonne1 shared publication
- Aurélie Guyoux
Research and Development Department NAOS Aix-en-Provence France
1 shared publication - Benoit Cadars1 shared publication
- Bibi Nusayha Sokeechand
Centre International de Développement Pharmaceutique (CIDP), BioPark, Socota Phoenicia, Sayed Hossen Road, Phoenix 73408, Mauritius
1 shared publication
Latest Publications
- 23 September 2022
- Published by Morressier GmbH
ESDR207 - An innovative preclinical mouse model of atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by highly pruritic inflamed skin lesions and dry skin. AD affects up | POSTER
- 23 September 2022
- Published by Morressier GmbH
ESDR207 - An innovative preclinical mouse model of atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by highly pruritic inflamed skin lesions and dry skin. AD affects up | POSTER
- 20 September 2022
- Published by Morressier GmbH
ESDR539 - Positive contribution of active molecules combined with sun filters evaluated by in vivo biomarkers analysis
Skin photoprotection has become a real public health issue. The major role of UVA rays has long been neglected, even though their harmful effect | POSTER
- 20 September 2022
- Published by Morressier GmbH
ESDR539 - Positive contribution of active molecules combined with sun filters evaluated by in vivo biomarkers analysis
Skin photoprotection has become a real public health issue. The major role of UVA rays has long been neglected, even though their harmful effect | POSTER
- Open Access
Clinical Evaluation of Indian Sandalwood Oil and Its Protective Effect on the Skin against the Detrimental Effect of Exposome
The skin is constantly subject to external stressors (the exposome), including particulate matter and blue light. These can penetrate the deeper layers of the skin, inducing the release of free radicals and triggering an inflammatory cascade of events contributing to cutaneous aging and exacerbating inflammatory skin conditions. This study demonstrates the clinical efficacy of Indian sandalwood oil of varying concentrations against oxidative stress induced by urban dust and blue light. Twenty-two healthy human subjects entered and completed the study of 11 days. Test products containing 0.1%, 1% and 10% of sandalwood oil, as well as a placebo and a comparator control (α-tocopherol), were applied on the different investigational zones of the upper back of each subject. Exposure ensued on day 7, using a controlled pollution exposure system (CPES) and blue light at a wavelength of 412 nm. Sebum was sampled on each investigational zone following the last exposure. The level of squalene monohydroperoxide (SQOOH) was the primary endpoint. A dose-dependent decrease in SQOOH on the zones treated with 10%, 1% and 0.1% of the sandalwood oil formulation compared to the untreated zones was observed. The zone treated with the 10% sandalwood-containing formula demonstrated the highest protective efficacy with the lowest amount of SQOOH. Increasing the concentration of the sandalwood oil increased its protective antioxidant activity. The results collected from this intraindividual comparative is the first clinical trial to suggest that sandalwood oil at a concentration between 1% and 10% protects the skin against the oxidative stress induced by urban dust and blue light exposure.
Open AccessClinical Evaluation of Indian Sandalwood Oil and Its Protective Effect on the Skin against the Detrimental Effect of Exposome
The skin is constantly subject to external stressors (the exposome), including particulate matter and blue light. These can penetrate the deeper layers of the skin, inducing the release of free radicals and triggering an inflammatory cascade of events contributing to cutaneous aging and exacerbating inflammatory skin conditions. This study demonstrates the clinical efficacy of Indian sandalwood oil of varying concentrations against oxidative stress induced by urban dust and blue light. Twenty-two healthy human subjects entered and completed the study of 11 days. Test products containing 0.1%, 1% and 10% of sandalwood oil, as well as a placebo and a comparator control (α-tocopherol), were applied on the different investigational zones of the upper back of each subject. Exposure ensued on day 7, using a controlled pollution exposure system (CPES) and blue light at a wavelength of 412 nm. Sebum was sampled on each investigational zone following the last exposure. The level of squalene monohydroperoxide (SQOOH) was the primary endpoint. A dose-dependent decrease in SQOOH on the zones treated with 10%, 1% and 0.1% of the sandalwood oil formulation compared to the untreated zones was observed. The zone treated with the 10% sandalwood-containing formula demonstrated the highest protective efficacy with the lowest amount of SQOOH. Increasing the concentration of the sandalwood oil increased its protective antioxidant activity. The results collected from this intraindividual comparative is the first clinical trial to suggest that sandalwood oil at a concentration between 1% and 10% protects the skin against the oxidative stress induced by urban dust and blue light exposure.